Revium Rx FY26 Q2 net loss narrows 28% to USD 748,000

• Revium Rx posted a net loss of USD 748,000 for the quarter ended June 30, 2026, narrowing 28% year over year.
• Operating loss improved 22% to USD 732,000, as general and administrative expense fell 47.2% to USD 289,000.
• Research and development expense rose 13.3% to USD 443,000, reflecting continued work to advance its lead programs.
• Cash and cash equivalents and short-term bank deposits totaled about USD 1.5 million at June 30, 2026; accumulated deficit was USD 26.4 million.
• Nano-Mupirocin advanced toward the clinic, with Israeli Ministry of Health approval on Feb. 18, 2026 to start Phase 1 trials in healthy volunteers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revium Rx. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-089070), on August 13, 2026, and is solely responsible for the information contained therein.